论文信息 - SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, IN COMBINATION WITH PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: RESULTS FROM A PHASE 2 STUDY - 字舞流文

SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, IN COMBINATION WITH PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: RESULTS FROM A PHASE 2 STUDY

M. Liedtke | J. Zonder | C. Quarta | M. Kurman | M. Harnett | S. Sobolov | J. Valent | J. Jobes | M. Spector | Julia Catini | E. Daniel | A. Bhattacharyya | J. Silowsky | Jessica Raviwong